1. Home
  2. GNL vs MYGN Comparison

GNL vs MYGN Comparison

Compare GNL & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNL
  • MYGN
  • Stock Information
  • Founded
  • GNL 2011
  • MYGN 1991
  • Country
  • GNL United States
  • MYGN United States
  • Employees
  • GNL N/A
  • MYGN N/A
  • Industry
  • GNL Real Estate Investment Trusts
  • MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • GNL Real Estate
  • MYGN Health Care
  • Exchange
  • GNL Nasdaq
  • MYGN Nasdaq
  • Market Cap
  • GNL 2.1B
  • MYGN 2.0B
  • IPO Year
  • GNL N/A
  • MYGN 1995
  • Fundamental
  • Price
  • GNL $7.68
  • MYGN $17.20
  • Analyst Decision
  • GNL Buy
  • MYGN Buy
  • Analyst Count
  • GNL 5
  • MYGN 12
  • Target Price
  • GNL $9.83
  • MYGN $28.18
  • AVG Volume (30 Days)
  • GNL 1.3M
  • MYGN 874.8K
  • Earning Date
  • GNL 11-06-2024
  • MYGN 11-07-2024
  • Dividend Yield
  • GNL 13.94%
  • MYGN N/A
  • EPS Growth
  • GNL N/A
  • MYGN N/A
  • EPS
  • GNL N/A
  • MYGN N/A
  • Revenue
  • GNL $812,621,000.00
  • MYGN $823,600,000.00
  • Revenue This Year
  • GNL N/A
  • MYGN $13.95
  • Revenue Next Year
  • GNL N/A
  • MYGN $9.71
  • P/E Ratio
  • GNL N/A
  • MYGN N/A
  • Revenue Growth
  • GNL 102.00
  • MYGN 12.15
  • 52 Week Low
  • GNL $6.52
  • MYGN $16.00
  • 52 Week High
  • GNL $10.19
  • MYGN $29.30
  • Technical
  • Relative Strength Index (RSI)
  • GNL 41.49
  • MYGN 21.06
  • Support Level
  • GNL $7.61
  • MYGN $16.86
  • Resistance Level
  • GNL $8.16
  • MYGN $19.60
  • Average True Range (ATR)
  • GNL 0.18
  • MYGN 1.13
  • MACD
  • GNL 0.00
  • MYGN -0.31
  • Stochastic Oscillator
  • GNL 48.67
  • MYGN 6.18

About GNL Global Net Lease Inc.

Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail ; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.

About MYGN Myriad Genetics Inc.

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Share on Social Networks: